See more : Dingdang Health Technology Group Ltd. (9886.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Alnylam Pharmaceuticals, Inc. (ALNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alnylam Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Diales Plc (DIAL.L) Income Statement Analysis – Financial Results
- Kikusui Holdings Corporation (6912.T) Income Statement Analysis – Financial Results
- Wan Hwa Enterprise Company Ltd. (2701.TW) Income Statement Analysis – Financial Results
- Credit Suisse Group AG (CSGN.SW) Income Statement Analysis – Financial Results
- MMG Limited (1208.HK) Income Statement Analysis – Financial Results
Alnylam Pharmaceuticals, Inc. (ALNY)
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.83B | 1.04B | 844.29M | 492.85M | 219.75M | 74.91M | 89.91M | 47.16M | 41.10M | 50.56M | 47.17M | 66.73M | 82.76M | 100.04M | 100.53M | 96.16M | 50.90M | 26.93M | 5.72M | 4.28M | 176.00K | 0.00 |
| Cost of Revenue | 310.41M | 168.82M | 140.14M | 78.05M | 25.06M | 1.80M | 13.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.52B | 868.60M | 704.14M | 414.80M | 194.69M | 73.11M | 76.55M | 47.16M | 41.10M | 50.56M | 47.17M | 66.73M | 82.76M | 100.04M | 100.53M | 96.16M | 50.90M | 26.93M | 5.72M | 4.28M | 176.00K | 0.00 |
| Gross Profit Ratio | 83.02% | 83.73% | 83.40% | 84.16% | 88.60% | 97.59% | 85.13% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.00B | 883.02M | 792.16M | 654.82M | 655.11M | 505.42M | 390.64M | 382.39M | 276.50M | 190.25M | 112.96M | 86.57M | 99.30M | 106.38M | 108.73M | 96.88M | 120.69M | 49.80M | 35.32M | 24.60M | 13.10M | 3.34M |
| General & Administrative | 795.65M | 770.66M | 620.64M | 588.42M | 479.01M | 382.36M | 199.37M | 89.35M | 60.61M | 44.53M | 27.15M | 44.61M | 38.28M | 37.73M | 39.91M | 27.12M | 23.39M | 16.63M | 13.87M | 11.94M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 795.65M | 770.66M | 620.64M | 588.42M | 479.01M | 382.36M | 199.37M | 89.35M | 60.61M | 44.53M | 27.15M | 44.61M | 38.28M | 37.73M | 39.91M | 27.12M | 23.39M | 16.63M | 13.87M | 11.94M | 7.53M | 880.00K |
| Other Expenses | 0.00 | -109.37M | -2.05M | 45.53M | 20.73M | 4.17M | -3.02M | 6.17M | 76.00K | 1.82M | -47.00K | 331.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.80B | 1.65B | 1.41B | 1.24B | 1.13B | 887.78M | 590.00M | 471.75M | 337.11M | 234.78M | 140.11M | 131.18M | 137.58M | 144.11M | 148.64M | 124.00M | 144.07M | 66.43M | 49.19M | 36.54M | 20.62M | 4.22M |
| Cost & Expenses | 2.11B | 1.82B | 1.55B | 1.32B | 1.16B | 889.58M | 590.00M | 471.75M | 337.11M | 234.78M | 140.11M | 131.18M | 137.58M | 144.11M | 148.64M | 124.00M | 144.07M | 66.43M | 49.19M | 36.54M | 20.62M | 4.22M |
| Interest Income | 95.56M | 24.81M | 1.58M | 11.81M | 33.45M | 29.26M | 12.24M | 8.31M | 5.86M | 2.56M | 1.07M | 977.00K | 1.21M | 2.31M | 5.39M | 14.41M | 15.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 121.22M | 155.97M | 143.02M | 84.50M | 0.00 | 29.26M | 12.24M | 8.31M | 5.86M | 2.56M | 1.07M | 977.00K | 1.21M | 2.31M | 5.39M | 872.00K | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 54.05M | 44.47M | 47.57M | 34.77M | 17.18M | 6.44M | 13.37M | 15.13M | 19.05M | 11.93M | 10.23M | 9.04M | 5.13M | 4.94M | 5.99M | 5.73M | 4.08M | 3.82M | 3.12M | 2.44M | 838.00K | 36.00K |
| EBITDA | -258.24M | -926.56M | -661.56M | -736.33M | -868.08M | -754.24M | -488.19M | -409.46M | -276.96M | -172.29M | -82.71M | -51.71M | -49.69M | -38.06M | -41.02M | -18.93M | -75.06M | -35.69M | -38.83M | -29.55M | -19.61M | -4.19M |
| EBITDA Ratio | -14.12% | -86.22% | -83.99% | -156.46% | -427.50% | -1,115.02% | -556.20% | -900.33% | -720.27% | 72.29% | -197.05% | -23.29% | -65.60% | -50.45% | -47.38% | -23.62% | -174.50% | -131.57% | -705.58% | -691.61% | -8,507.39% | 0.00% |
| Operating Income | -282.18M | -785.07M | -708.65M | -828.44M | -939.43M | -814.67M | -500.09M | -424.59M | -296.01M | -404.98M | -92.94M | -129.46M | -54.82M | -44.07M | -48.11M | -27.84M | -93.18M | -39.50M | -43.47M | -32.26M | -25.06M | -4.22M |
| Operating Income Ratio | -15.43% | -75.68% | -83.93% | -168.09% | -427.50% | -1,087.56% | -556.20% | -900.33% | -720.27% | -800.97% | -197.05% | -194.01% | -66.24% | -44.05% | -47.86% | -28.95% | -183.07% | -146.68% | -760.53% | -754.18% | -14,236.93% | 0.00% |
| Total Other Income/Expenses | -151.34M | -341.92M | -143.49M | -27.16M | 54.18M | 54.00M | 9.21M | 14.48M | 5.94M | 4.38M | 1.02M | 12.87M | -2.83M | 1.07M | 1.10M | 2.31M | 12.96M | 4.89M | 558.00K | -390.00K | -4.64M | 0.00 |
| Income Before Tax | -433.52M | -1.13B | -852.14M | -855.60M | -885.25M | -760.67M | -490.87M | -410.11M | -290.07M | -400.60M | -91.92M | -116.59M | -57.65M | -43.00M | -47.01M | -25.53M | -80.22M | -34.61M | -42.91M | -35.37M | -29.69M | 0.00 |
| Income Before Tax Ratio | -23.71% | -108.63% | -100.93% | -173.60% | -402.85% | -1,015.48% | -545.95% | -869.63% | -705.83% | -792.32% | -194.88% | -174.73% | -69.66% | -42.98% | -46.76% | -26.55% | -157.61% | -128.51% | -750.77% | -826.72% | -16,871.59% | 0.00% |
| Income Tax Expense | 6.73M | 4.16M | 680.00K | 2.68M | 863.00K | 823.00K | -25.60M | -23.44M | -24.91M | -40.21M | -2.70M | -10.57M | -5.80M | 514.00K | 582.00K | 719.00K | 5.25M | -4.89M | -558.00K | 390.00K | 4.59M | -86.00K |
| Net Income | -440.24M | -1.13B | -852.82M | -858.28M | -886.12M | -761.50M | -490.87M | -410.11M | -290.07M | -360.40M | -89.23M | -106.01M | -57.65M | -43.52M | -47.59M | -26.25M | -85.47M | -34.61M | -42.91M | -32.65M | -25.03M | -4.14M |
| Net Income Ratio | -24.08% | -109.04% | -101.01% | -174.15% | -403.24% | -1,016.58% | -545.95% | -869.63% | -705.83% | -712.79% | -189.17% | -158.88% | -69.66% | -43.50% | -47.34% | -27.30% | -167.92% | -128.51% | -750.77% | -763.30% | -14,223.30% | 0.00% |
| EPS | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
| EPS Diluted | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
| Weighted Avg Shares Out | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.60M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | 41.63M | 41.08M | 38.66M | 31.89M | 21.95M | 11.89M | 942.67K | 331.34K |
| Weighted Avg Shares Out (Dil) | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.60M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | 41.63M | 41.08M | 38.66M | 31.89M | 21.95M | 11.89M | 942.67K | 331.34K |
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
ALNY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.
Levi & Korsinsky Reminds Alnylam Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ALNY
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY
ALNY STOCK ALERT: Levi & Korsinsky Notifies Alnylam Pharmaceuticals, Inc. Investors of an Ongoing Investigation
Source: https://incomestatements.info
Category: Stock Reports